CPBIO Holding Company Limited (CAIHF)

Market Cap	245.35M +8.9%
Revenue (ttm)	423.98M -18.9%
Net Income	24.43M -6.9%
EPS	0.10 -6.9%
Shares Out	n/a
PE Ratio	11.07
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10
Open	0.280
Previous Close	1.068
Day's Range	0.002 - 1.068
52-Week Range	1.068 - 1.068
Beta	4.06
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 11, 2026

About CPBIO Holding Company

CPBIO Holding Company Limited manufactures and sells animal health products and chlortetracycline in Mainland China, the Asia Pacific, the Americas, Europe, and internationally. It operates through two segments: Biotech Business and Investment Business. The Biochemical segment is engaged in the manufacture and/or sale of animal health products and chlortetracycline, which are used as feed additives to promote growth of livestock, prevent or cure animal diseases, and enhance efficiency under the Shihao and Citifac brand names. The company offers...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1987
• Employees: 1,000
• Stock Exchange: OTCMKTS
• Ticker Symbol: CAIHF

Financial Performance

In 2025, CPBIO Holding Company's revenue was $535.91 million, an increase of 74.14% compared to the previous year's $307.75 million. Earnings were $32.06 million, an increase of 187.03%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 9, 2026

Data Sources Report a data error